TTM Capital was awarded "Top 10 Emerging Investment Institutions in China" & "Top 30 Outstanding Innovators in China's Private Equity Investment"
At the beginning of the new year, TTM Capital welcomed a "good start." On January 13, the annual list of equity investment in China was announced, and TTM Capital was awarded the "Top 10 Emerging Investment Institutions in China." LILY ZHANG, the founding managing partner of TTM Capital, was awarded the "Top 30 Outstanding Innovators in China's Equity Investment."
At the beginning of the new year, TTM Capital welcomed a "good start." On January 13, the annual list of equity investment in China was announced, and TTM Capital was awarded the "Top 10 Emerging Investment Institutions in China." LILY ZHANG, the founding managing partner of TTM Capital, was awarded the "Top 30 Outstanding Innovators in China's Equity Investment."
Thanks to the organization and recognition from China Bridge. The annual list of equity investments by China Financing has been published for 10 consecutive years, covering active institutions in the Chinese private equity market. It is an important reference for interpreting future trends and investment directions in the industry, and this list is also considered one of the most influential rankings in the industry.
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
